94. Primary sclerosing cholangitis Disease details / Clinical trials / Drug dev / DR info


Clinical trials : 148 Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141

Drugs and their primary sponsors and trial info
11C-CSar   
   University of Aarhus
      2013   Phase 1   NCT01879735   Denmark;
3108006977   
   RIEMSER Arzneimittel AG
      2005   -   EUCTR2005-001454-24-LT   Lithuania;
ACIDO DEOSSICOLICO   
   DR. FALK PHARMA GMBH
      2018   Phase 3   EUCTR2016-003367-19-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;
ACIDO OBETICOLICO   
   INTERCEPT PHARMACEUTICALS INC.
      2015   Phase 2   EUCTR2014-002205-38-IT   Italy;United States;
AZT   
   Tajiri Hitoshi
      2012   Phase 2   JPRN-jRCTs051180120   Japan;
All-trans retinoic acid   
   Yale University
      2018   Phase 2   NCT03359174   United States;
Azathioprine   
   Osaka General Medical Center
      2012   -   JPRN-UMIN000029482   Japan;
   Tajiri Hitoshi
      2012   Phase 2   JPRN-jRCTs051180120   Japan;
BEFIZAL L.P. 400 mg, comprimé enrobé à libération prolongée   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2020   Phase 3   EUCTR2019-001015-23-FR   France;
BTT1023   
   University of Birmingham
      2015   Phase 2   NCT02239211   United Kingdom;
BTT1023 IV Infusion 20 mg/mL, 5 mL Drug Product   
   University of Birmingham
      2015   Phase 2   EUCTR2014-002393-37-GB   United Kingdom;
Bezafibrate   
   Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)
      2016   Phase 3   NCT02701166   Netherlands;Spain;
Bezafibrate (400mg) in addition to standard 15-20 mg/kg/jour UDCA therapy   
   Assistance Publique - Hôpitaux de Paris
      2021   Phase 3   NCT04309773   France;
Bezalip   
   Academic Medical Center
      2017   Phase 2   EUCTR2014-001438-27-ES   Netherlands;Spain;
      2015   -   EUCTR2014-001438-27-NL   Netherlands;
Budesonide   
   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
      1997   Phase 1   NCT00004842   United States;
C10AB02   
   ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
      2020   Phase 3   EUCTR2019-001015-23-FR   France;
CILO   
   Gilead Sciences
      2019   Phase 1   NCT04060147   United States;
CM-101   
   ChemomAb Ltd
      2022   Phase 2   EUCTR2019-002945-39-ES   Israel;Spain;United Kingdom;
      2020   Phase 2   EUCTR2019-002945-39-GB   Israel;United Kingdom;
   ChemomAb Ltd.
      2020   Phase 2   NCT04595825   Germany;Israel;United Kingdom;
      2019   Phase 2   EUCTR2018-004258-77-GB   Israel;United Kingdom;
CS0159   
   Cascade Pharmaceuticals, Inc
      2021   Phase 1   NCT05082779   United States;
Capecitabine   
   Azienda Ospedaliera di Padova
      2012   -   NCT01549795   Italy;
Cenicriviroc   
   Tobira Therapeutics, Inc.
      2016   Phase 2   NCT02653625   Canada;United States;
Cilofexor   
   GILEAD SCIENCES INCORPORATED
      2019   Phase 3   EUCTR2019-000204-14-IT   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
   Gilead Sciences
      2019   Phase 3   NCT03890120   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;New Zealand;Spain;Switzerland;United Kingdom;United States;
      2016   Phase 2   NCT02943460   Austria;Canada;United Kingdom;United States;
      2016   Phase 1   NCT02808312   New Zealand;United States;
   Gilead Sciences, Inc.
      2019   Phase 3   EUCTR2019-000204-14-GB   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-FR   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-FI   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-ES   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-DK   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-AT   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
Cis-4-Hydroxy-L-Proline   
   RIEMSER Arzneimittel AG
      2005   -   EUCTR2005-001454-24-LT   Lithuania;
Cladribine   
   National Center for Research Resources (NCRR)
      1994   Phase 2   NCT00004762   -
Curcumin   
   John E. Eaton
      2017   Phase 1/Phase 2   NCT02978339   United States;
DUR-928   
   Durect
      2018   Phase 2   NCT03394781   United States;
Docosahexaenoic Acid (DHA)   
   Beth Israel Deaconess Medical Center
      2005   Phase 1   NCT00325013   United States;
Engineered recombinant human FGF19   
   NGM Biopharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-003392-30-NL   France;Netherlands;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003392-30-GB   France;Netherlands;United Kingdom;United States;
Entyvio   
   TAKEDA DEVELOPMENT CENTRE EUROPE LTD
      2016   Phase 3   EUCTR2014-003942-28-IT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
   Takeda Development Centre Europe, Ltd.
      2016   Phase 3   EUCTR2014-003942-28-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Erlotinib (Tarceva)   
   Mayo Clinic
      2009   Phase 1   NCT00955149   United States;
FLUIMUCIL*20CPR EFF   
   POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
      2012   -   EUCTR2012-004170-26-IT   Italy;
Fecal Microbiota Transplantation   
   Brigham and Women's Hospital
      2016   Phase 1/Phase 2   NCT02424175   United States;
Fenofibrate   
   University of Miami
      2010   Phase 1/Phase 2   NCT01142323   United States;
GS-6624   
   Gilead Sciences Inc
      2013   Phase 2   EUCTR2012-002473-61-SE   Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-002473-61-NL   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-002473-61-IT   Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-002473-61-GB   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-002473-61-ES   Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-002473-61-DK   Belgium;Canada;Denmark;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-002473-61-DE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
      2013   Phase 2   EUCTR2012-002473-61-BE   Belgium;Canada;Denmark;France;Germany;Italy;Netherlands;Norway;Spain;Sweden;United Kingdom;United States;
GS-9674   
   GILEAD SCIENCES INCORPORATED
      2019   Phase 3   EUCTR2019-000204-14-IT   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
   Gilead Sciences, Inc.
      2019   Phase 3   EUCTR2019-000204-14-GB   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-FR   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-FI   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-ES   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-DK   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2019   Phase 3   EUCTR2019-000204-14-AT   Australia;Austria;Belgium;Canada;Denmark;Finland;France;Germany;Israel;Italy;Japan;Netherlands;New Zealand;Spain;Sweden;Switzerland;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002442-23-GB   Austria;Canada;United Kingdom;United States;
      2017   Phase 2   EUCTR2016-002442-23-AT   Austria;Canada;United Kingdom;United States;
Gluten-free diet   
   Universitätsklinikum Hamburg-Eppendorf
      2017   -   NCT04006886   Germany;
HTD1801   
   HighTide Biopharma Pty Ltd
      2021   Phase 2   NCT03678480   -
      2018   Phase 2   NCT03333928   Canada;United States;
      2017   Phase 1   NCT03099603   Australia;
Humanised IgG1 monoclonal antibody against human eotaxin-2   
   ChemomAb Ltd
      2022   Phase 2   EUCTR2019-002945-39-ES   Israel;Spain;United Kingdom;
      2020   Phase 2   EUCTR2019-002945-39-GB   Israel;United Kingdom;
ICG   
   University of Aarhus
      2013   Phase 1   NCT01879735   Denmark;
INT-747, OCA   
   INTERCEPT PHARMACEUTICALS INC.
      2015   Phase 2   EUCTR2014-002205-38-IT   Italy;United States;
LUM001   
   Lumena Pharmaceuticals LLC
      2015   Phase 2   EUCTR2014-005558-21-GB   United Kingdom;United States;
   Mirum Pharmaceuticals, Inc.
      2014   Phase 2   NCT02061540   Canada;United Kingdom;United States;
MBX-8025   
   CymaBay Therapeutics
      2019   Phase 2   EUCTR2019-001760-30-PL   Australia;Canada;Germany;Israel;Poland;United Kingdom;United States;
      2019   Phase 2   EUCTR2019-001760-30-GB   Australia;Canada;Germany;Israel;Poland;United Kingdom;United States;
MLN0002   
   Takeda Development Centre Europe, Ltd.
      2016   Phase 3   EUCTR2014-003942-28-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Metronidazole   
   Cliniques universitaires Saint-Luc- Université Catholique de Louvain
      2016   -   NCT03069976   Belgium;
   Keio University, School of Medicine
      2016   -   JPRN-UMIN000021411   Japan;
   Mayo Clinic
      2010   Phase 1   NCT01085760   United States;
Minocycline   
   Mayo Clinic
      2003   Phase 1   NCT00630942   United States;
Mitomycin C   
   Li, Zhiping, M.D.
      2012   Phase 2   NCT01688024   United States;
Mizoribine   
   Osaka General Medical Center
      2012   -   JPRN-UMIN000029482   Japan;
   Tajiri Hitoshi
      2012   Phase 2   JPRN-jRCTs051180120   Japan;
NGM282   
   NGM Biopharmaceuticals, Inc
      2016   Phase 2   NCT02704364   France;Netherlands;United Kingdom;United States;
   NGM Biopharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-003392-30-NL   France;Netherlands;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003392-30-GB   France;Netherlands;United Kingdom;United States;
NorUDCA   
   Dr. Falk Pharma GmbH
      2019   Phase 3   EUCTR2016-003367-19-NL   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-PL   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-GB   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-FR   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2016-003367-19-LT   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2016-003367-19-HU   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2014   -   EUCTR2011-002754-31-BE   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2013   Phase 2   EUCTR2011-002754-31-GB   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   Phase 2   NCT01755507   Austria;Germany;Norway;
      2012   Phase 2   EUCTR2011-002754-31-SE   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   Phase 2   EUCTR2011-002754-31-NO   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2011-002754-31-NL   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2011-002754-31-LT   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2011-002754-31-HU   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2011-002754-31-FI   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2011-002754-31-ES   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2011-002754-31-DK   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2011-002754-31-DE   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      2012   -   EUCTR2011-002754-31-AT   Austria;Belgium;Denmark;Finland;Germany;Hungary;Lithuania;Netherlands;Norway;Spain;Sweden;United Kingdom;
      -   Phase 3   EUCTR2016-003367-19-IE   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Lithuania;Netherlands;Poland;Sweden;Switzerland;United Kingdom;
NorUDCA (Norursodeoxycholic acid)   
   DR. FALK PHARMA GMBH
      2018   Phase 3   EUCTR2016-003367-19-IT   Austria;Belgium;Czech Republic;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Sweden;Switzerland;United Kingdom;
Normal saline   
   Li, Zhiping, M.D.
      2012   Phase 2   NCT01688024   United States;
Norucholic acid   
   Dr. Falk Pharma GmbH
      2018   Phase 3   EUCTR2016-003367-19-SE   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-FI   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-DK   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-CZ   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-BE   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2016-003367-19-DE   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2016-003367-19-AT   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2016-003367-19-NO   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
Norursodeoxycholic acid, NCA   
   Dr. Falk Pharma GmbH
      2018   Phase 3   EUCTR2016-003367-19-SE   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-FI   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-DK   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-CZ   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2018   Phase 3   EUCTR2016-003367-19-BE   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2016-003367-19-DE   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      2017   Phase 3   EUCTR2016-003367-19-AT   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
      -   Phase 3   EUCTR2016-003367-19-NO   Austria;Belgium;Czech Republic;Czechia;Denmark;Finland;France;Germany;Hungary;Ireland;Italy;Lithuania;Netherlands;Norway;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;
OCA   
   Intercept Pharmaceuticals
      2015   Phase 2   NCT02177136   Austria;Belgium;France;Germany;Italy;Netherlands;Norway;Sweden;United Kingdom;United States;
OCA 1,   
   INTERCEPT PHARMACEUTICALS INC.
      2015   Phase 2   EUCTR2014-002205-38-IT   Italy;United States;
Oral Vancomycin   
   Sacramento Pediatric Gastroenterology
      2010   Phase 1   NCT02137668   United States;
   Stanford University
      2012   Phase 3   NCT01802073   United States;
Oral all-trans retinoic acid (ATRA)   
   Yale University
      2011   Phase 1   NCT01456468   United States;
Orbcel-C   
   University of Birmingham
      2018   Phase 1/Phase 2   NCT02997878   United Kingdom;
PLN-74809   
   Pliant Therapeutics, Inc
      2021   Phase 2   EUCTR2020-001428-33-NL   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States;
      2021   Phase 2   EUCTR2020-001428-33-DE   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;United Kingdom;United States;
      2020   Phase 2   EUCTR2020-001428-33-GB   Australia;Austria;Belgium;Canada;France;Germany;Netherlands;Norway;United Kingdom;United States;
   Pliant Therapeutics, Inc.
      2020   Phase 2   NCT04480840   Australia;Austria;Belgium;Canada;Germany;Netherlands;United Kingdom;United States;
Phenylbutyrate   
   Juntendo University
      2014   -   JPRN-UMIN000012782   Japan;
   Saiseikai Yokohama City Tobu Hospital
      2010   -   JPRN-UMIN000003802   Japan;
Pre liver transplantation laparoscopic hand assisted staging   
   Azienda Ospedaliera di Padova
      2012   -   NCT01549795   Italy;
Probiotics   
   UMC Utrecht
      2005   Phase 3   NCT00161148   Netherlands;
Rec-h-FGF19   
   NGM Biopharmaceuticals, Inc.
      2016   Phase 2   EUCTR2015-003392-30-NL   France;Netherlands;United Kingdom;United States;
      2016   Phase 2   EUCTR2015-003392-30-GB   France;Netherlands;United Kingdom;United States;
Rituximab   
   Keio University Hospital
      2016   -   JPRN-UMIN000022897   Japan;
Seladelpar   
   CymaBay Therapeutics, Inc.
      2019   Phase 2   NCT04024813   Canada;Poland;United States;
Simtuzimab   
   Gilead Sciences Inc
      2013   Phase 2   EUCTR2012-002473-61-IT   Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Simtuzumab   
   Gilead Sciences
      2013   Phase 2   NCT01672853   Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
   Gilead Sciences Inc
      2013   Phase 2   EUCTR2012-002473-61-IT   Belgium;Canada;Denmark;Germany;Italy;Netherlands;Spain;Sweden;United Kingdom;United States;
Simvastatin   
   Annika Bergquist
      2020   Phase 3   NCT04133792   Sweden;
Sulfasalazine   
   Brigham and Women's Hospital
      2018   Phase 2   NCT03561584   United States;
TBC   
   ChemomAb Ltd
      2022   Phase 2   EUCTR2019-002945-39-ES   Israel;Spain;United Kingdom;
      2020   Phase 2   EUCTR2019-002945-39-GB   Israel;United Kingdom;
Thalidomide   
   Mayo Clinic
      2006   Phase 2   NCT00953615   United States;
UCMSC   
   Fuzhou General Hospital
      2017   Phase 1/Phase 2   NCT03516006   -
UDCA   
   Fuzhou General Hospital
      2017   Phase 1/Phase 2   NCT03516006   -
Ursodeoxycholic acid (UDCA)   
   University of Tennessee
      2010   Phase 1   NCT01088607   Canada;United States;
Ursofalk   
   Sahlgrenska Academy
      2015   Phase 3   EUCTR2015-003310-24-SE   Sweden;
Ursolic acid   
   University of California, Davis
      2017   Phase 1   NCT03216876   United States;
Vancomycin   
   Elizabeth Carey
      2020   Phase 2/Phase 3   NCT03710122   Canada;United States;
   Karolinska Institutet
      2013   -   EUCTR2009-018034-11-SE   Sweden;
   Mayo Clinic
      2010   Phase 1   NCT01085760   United States;
   Ochsner Health System
      2016   -   NCT03046901   United States;
   Stanford University
      2007   Phase 1   NCT01322386   -
   Tehran University of Medical Sciences
      2015   Phase 4   NCT02605213   Iran, Islamic Republic of;
   University of Minnesota
      2015   Phase 1   NCT02464020   United States;
Vedolizumab   
   Takeda
      2017   Phase 3   NCT03035058   -
Vedolizumab IV   
   Takeda Development Centre Europe, Ltd.
      2016   Phase 3   EUCTR2014-003942-28-SE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-PL   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-HU   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-GB   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-FR   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-ES   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-DE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-CZ   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-BE   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
      2016   Phase 3   EUCTR2014-003942-28-AT   Austria;Belgium;Bulgaria;Canada;Czech Republic;Denmark;Finland;France;Germany;Hungary;Israel;Italy;Japan;Netherlands;Poland;Russian Federation;Spain;Sweden;Switzerland;United Kingdom;United States;
Vidofludimus calcium   
   Elizabeth Carey
      2019   Phase 2   NCT03722576   United States;
Volixibat   
   Mirum Pharmaceuticals, Inc.
      2020   Phase 2   NCT04663308   United States;
Volixibat (formely SHP626, LUM002 or SAR548304B)   
   Mirum Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-003027-41-DE   Canada;Germany;Israel;United Kingdom;United States;
Volixibat potassium   
   Mirum Pharmaceuticals, Inc.
      2021   Phase 2   EUCTR2020-003027-41-DE   Canada;Germany;Israel;United Kingdom;United States;
Xifaxan   
   Mayo Clinic
      2012   Phase 1   NCT01695174   United States;
[18F]FP-R01-MG-F2   
   Stanford University
      2017   Early Phase 1   NCT03183570   United States;